Prostate News and Research

RSS

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

A new effort led by a University of California, Irvine Medical Center oncologist seeks to improve cancer survival for adolescents and young adults. Dr. Leonard S. Sender has long advocated changing the approach oncologists take when treating patients and survivors aged 15 to 39.

7 May 2011

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.

7 May 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.

5 May 2011

WWP2 protein appears to play a key role in tumor survival

A protein known as WWP2 appears to play a key role in tumor survival, a research team headed by a scientist at The University of Texas MD Anderson Cancer Center reports in an advance online publication of Nature Cell Biology.

4 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

Statins can help reduce lung damage in severe abdominal sepsis

Statins may be best known for their ability to reduce cholesterol, but a research report appearing in the May 2011 issue of the Journal of Leukocyte Biology shows that these same drugs could also play a crucial role in the reduction of lung damage resulting from severe abdominal sepsis and infection.

3 May 2011

Prenatal exposure to BPA linked with wheezing in children

If a pregnant woman is exposed to bisphenol A, especially during the first trimester, her child may be at higher risk of wheezing early in life, according to a study to be presented Sunday, May 1, at the Pediatric Academic Societies annual meeting in Denver.

2 May 2011

Porter Adventist Hospital introduces new institute for robotic surgery

Robotic surgery, once the stuff of science fiction, has for some years been recognized as an important advance in surgical technique and patient experience. Now, at Porter Adventist Hospital, a comprehensive team of surgeons and staff are helping to bring in a new era in robotic surgery.

2 May 2011

USHIFU announces results from clinical investigation of Sonablate HIFU to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.

30 Apr 2011

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to a study presented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

Omega 3 rich oils fall from grace: May raise prostate cancer risk

...

26 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Prostate News and Research

OncoGenex first quarter revenue decreases to $1.2 million

GTx reports net loss of $2.6 million for first quarter 2011

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Surgery reduces mortality risk of prostate cancer

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

WWP2 protein appears to play a key role in tumor survival

FDA approves new targeted therapy to treat men with advanced prostate cancer

Statins can help reduce lung damage in severe abdominal sepsis

Prenatal exposure to BPA linked with wheezing in children

Porter Adventist Hospital introduces new institute for robotic surgery

USHIFU announces results from clinical investigation of Sonablate HIFU to treat prostate cancer

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Scripps Research receives $1.9 million NIH grant for prostate cancer study

Omega 3 rich oils fall from grace: May raise prostate cancer risk

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News